Risk of Recurrent Venous Thromboembolism and Mortality in Patients With Cancer Incidentally Diagnosed With Pulmonary Embolism: A Comparison With Symptomatic Patients On the basis of a nationwide MPN ...

Investigators from China used circulating tumor DNA testing alongside bone marrow assessments to evaluate patients' pretreatment and posttreatment disease levels and to track the course of the disease ...

The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.

Venclexta-based regimens showed survival benefits in AML and MDS, with a two-year overall survival rate of 46% and median survival of 18.73 months. Remission was achieved by 57.1% of AML patients and ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. So, in terms of preventing MDS, that's a ...

CareDx CDNA recently announced clinical validation data supporting AlloHeme, its next-generation, blood-based monitoring test designed to predict relapses in patients with acute myeloid leukemia (AML) ...

Ultra‑Sensitive, Non‑Invasive Surveillance Solution Expected to Launch Commercially in the U.S. in 2027 as Part of CareDx’s Transplant+ Precision Medicine Portfolio BRISBANE, Calif., February 12, 2026 ...

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation. In myelodysplastic ...

GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of ...